The IL18 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human osteosarcoma 143B cell line, engineered to disrupt expression of the IL18 gene. This population contains a heterogeneous mix of cells with distinct editing events, generating a loss-of-function model for studying IL18-mediated signaling without clonal isolation.
The 143B cell line is a widely utilized human osteosarcoma model, originally derived from a patient with osteosarcoma. These cells exhibit aggressive tumorigenic properties, including rapid proliferation, invasive capacity, and the ability to form tumors in vivo, making them a relevant system for bone cancer research and the study of tumor?Cmicroenvironment interactions.
IL18 is a pro-inflammatory cytokine that plays a central role in innate and adaptive immunity. It is primarily activated by caspase-1 downstream of NLRP3 inflammasome assembly in response to stimuli such as lipopolysaccharide (LPS). Secreted IL18 binds to its heterodimeric receptor complex, comprised of IL18R1 and IL18RAP, recruiting the adaptor protein MyD88. This initiates a signaling cascade involving IRAK4 and TRAF6, leading to activation of the NF-??B and MAPK pathways. Consequently, IL18 drives the production of interferon-gamma (IFN-??) and tumor necrosis factor (TNF), and promotes the differentiation of Th1 cells and activation of NK cells. The IL18 signaling axis is tightly regulated by the decoy receptor IL18 binding protein (IL18BP).
In the context of osteosarcoma, IL18 contributes to an inflammatory microenvironment that can influence tumor progression and immune evasion. Knockout of IL18 in 143B cells disrupts the autocrine and paracrine IL18 signaling, thus impairing downstream NF-??B and MAPK pathway activation, and potentially reducing the production of secondary inflammatory mediators. This polyclonal knockout population provides a useful tool to dissect the role of IL18 in bone cancer-associated inflammation and to evaluate the crosstalk between tumor cells and immune cells, particularly Th1-mediated responses.
This product is suitable for a variety of experimental approaches, including ELISA-based quantification of secreted cytokines, western blot analysis of NF-??B and MAPK phosphorylation, and RT-qPCR measurement of IFN-?? and TNF transcript levels. Functional assays such as invasion assays and co-culture systems with immune cells can be employed to examine the impact of IL18 loss on tumor cell behavior and immune cell recruitment. Additionally, flow cytometry can be used to assess Th1 markers in co-cultured lymphocytes. These polyclonal knockout cells serve as a valuable model for investigating IL18 function in tumor immunity, inflammatory bone diseases, and cytokine signaling in osteosarcoma. For further details or technical assistance, please contact Ascent Research.
